Enter The Phantom Masked Coordinator!!
CLICK HERE > https://tiurll.com/2t3xmB
Layout table for study information Study Type : Interventional (Clinical Trial) ActualEnrollment : 144 participants Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: The primary endpoint at 4 months following the initial treatment will utilize a parallel group study design; however, an optional crossover is offered to subjects following this time point. Masking: Triple (Participant, Investigator, Outcomes Assessor) Masking Description: All individuals will be masked to treatment with the exception of the anesthesiologist administering the procedure who will choose which probe to use: the functional or sham. Of note, this individual could not be masked to treatment since the cryoneurolysis ice ball is visualized on ultrasound; and, the practitioner would see a lack of ice ball formation for the sham probes. Primary Purpose: Treatment Official Title: Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Definitive Human Subjects Clinical Trial Actual Study Start Date : March 23, 2018 Actual Primary Completion Date : August 17, 2021 Actual Study Completion Date : March 17, 2022 Arms and Interventions Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Arm Intervention/treatment Active Comparator: CryoneurolysisCryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis. Device: CryoneurolysisCryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.Other Name: Cryoanalgesia Sham Comparator: Sham ComparatorSham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis. Device: Sham ComparatorSham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.Other Name: placebo, control Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : Average daily phantom pain intensity [ Time Frame: Baseline and 4 months later (difference between the two is the primary end point) ]The difference in average daily phantom pain intensity at baseline and 4 months following the initial intervention (measured with the NRS as part of the Brief Pain Inventory) Secondary Outcome Measures : Average daily phantom pain intensity [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]The difference in average daily phantom pain intensity at baseline and various time points other than the primary at 4 months Brief Pain Inventory [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]The difference in the Brief Pain Inventory between baseline and various time points Residual limb pain (frequency and duration) [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]Pain that originates from a part of the injured limb that remains intact Patient Global Impression of Change [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]A 7-point scale of change from baseline at various time points Beck Depression Inventory [ Time Frame: At baseline, 4 months, 12 months (and 4 months following crossover for those subjects who choose to the crossover treatment) ]21-question questionnaire evaluating depression with 4-5 multiple choice responses Non-painful phantom sensations (frequency and duration) [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]Sensations that feel to emanate from the missing limb, but are not described as pain Phantom limb pain (frequency and duration) [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]Pain perceived to emanate from part of the injured limb that no longer exists Residual limb pain (NRS) [ Time Frame: Endpoints will be evaluated at baseline and post-treatment (Day 0), Days 1 and 7; and Months 1, 2, 3, 4, and 12 [same for crossover subjects with the exception of the 12-month time point] ]Pain that originates from a part of the injured limb that remains intact. Worst, least, average, and current pain levels will be recorded at each time point Eligibility CriteriaGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria:
Ina sense, Murnau's film is about all of the things we worry about at 3 in themorning--cancer, war, disease, madness. It suggests these dark fears in thevery style of its visuals. Much of the film is shot in shadow. The corners ofthe screen are used more than is ordinary; characters lurk or cower there, andit's a rule of composition that tension is created when the subject of a shotis removed from the center of the frame. Murnau's special effects add to thedisquieting atmosphere: the fast motion of Orlok's servant, the disappearanceof the phantom coach, the manifestation of the count out of thin air, the useof a photographic negative to give us white trees against a black sky. 2b1af7f3a8
https://sway.office.com/lwK7ygDUdY8q2XPz
https://sway.office.com/4VIfXnofAaCdxRqA
https://sway.office.com/ScAJHu1r54H7Dvyb
https://sway.office.com/GGM52KXNVrk8uuSO
https://sway.office.com/S0QxetvVETQ1suCv
https://sway.office.com/jsgDZNfTD8katMY3
https://sway.office.com/pEtdvSNRroV1NYqn
https://sway.office.com/LSbcspgdDVenGn2b
https://sway.office.com/VwQUGYgnTa54ENiB
https://sway.office.com/lXWqaS3NYz60zWs6
https://sway.office.com/870dFhDb7Bk43Q3R
https://sway.office.com/hjbR6rzFLo5ejXYV
https://sway.office.com/mKJ8vvNIF0jkSu7K
https://sway.office.com/CLOhZx4mPsDZdbjr
https://sway.office.com/b21vuZSL1zRVh6Ah
https://sway.office.com/XWoFUu7RCADsUIhi
https://sway.office.com/1NaXbHdsmWF6OGSf
https://sway.office.com/y1BGQOq2608ZIP7o
https://sway.office.com/UrmUFmbgMxZ1fEuM
https://sway.office.com/vRaxOy2y7SyBlY6v
https://sway.office.com/PSzOmKFGSlgRsAld
https://sway.office.com/0A2ZQhGKlf8MrH4U
https://sway.office.com/jrcHjmYDPvrgeFkS
https://sway.office.com/w0dqJN2dDFNhoHJu
https://sway.office.com/PpKUUxrqARCkDe8p
https://sway.office.com/Qh1lRglJKUmM67Fn
https://sway.office.com/CSqtkC07zKCV05Kn
https://sway.office.com/W7FkbGDujEB27iYS
https://sway.office.com/jzncBjFlD1vjUxxl
https://sway.office.com/9i7QlSouGH9GWptO
https://sway.office.com/ONuScA50CrtqlLoB
https://sway.office.com/2mIiHj8Fn90huIML
https://sway.office.com/hWkC498qjgPHkFn2
https://sway.office.com/fpsug1zyBcEp0X8l
https://sway.office.com/vyEZosnkQMQYJxKb
https://sway.office.com/MhBxQGoNwQ7WVCIA
https://sway.office.com/nx10IVxSSc3v2cAp
https://sway.office.com/o0wda3iGWFCBcon5
https://sway.office.com/aSZ2uRznttXC64Iq
https://sway.office.com/B74J7GQCvynYzjGP
https://sway.office.com/xRU90XGA8DtFzFYa
https://sway.office.com/v6r4N1hD0DVwfSUu
https://sway.office.com/DOnFejU3t0OmyIGw
https://sway.office.com/ZUdUFp49gx2WJxRf
https://sway.office.com/w73sOgpv6WSYNYxc
https://sway.office.com/o2U0M0WmRRox3e9k
https://sway.office.com/YXXVhNYkdS4utUAH
https://sway.office.com/3ALtRKQn92j35lBD
https://sway.office.com/GojXhf9gG2SM239s
https://sway.office.com/rgQl0bVZe0GacU1S
https://sway.office.com/l8bWq6p8Fu7xlD35
https://sway.office.com/75L9tovPh72mwhOF
https://sway.office.com/KN4bKoc9ios2BpDn
https://sway.office.com/WrTI9ErzmXmzQDJq
https://sway.office.com/7FOr7hVbFqoXBgwg
https://sway.office.com/EbCUn8YF1rE4okAs
https://sway.office.com/g6vwDPbjaIXe3y6S
https://sway.office.com/C9TGt2QylFw9XL66
https://sway.office.com/zZwmFqMe0l4BvnBr
https://sway.office.com/p0lgE62mlGWyaVAR
https://sway.office.com/h3RUHxIePIkDzv5e
https://sway.office.com/ogRvdPXV5MsfKKjB
https://sway.office.com/aMdelTcUc00I2eJe
https://sway.office.com/m1cI0iaBKlKDuBmM
https://sway.office.com/yIdTOCBxedvJgTEB
https://sway.office.com/LbORmMvJ5rCfVUFQ
https://sway.office.com/OnhlKkIHUsorEIPu
https://sway.office.com/eStDkZJ13SaBbpML
https://sway.office.com/FXD5yVD7A5h0kHeG
https://sway.office.com/GnAihnbWecbEFy5Z
https://sway.office.com/KFKQKdh9Nm5kuncM
https://sway.office.com/qe8IeMaI1fuL9U4v
https://sway.office.com/U3CQY563wZG3IKzu
https://sway.office.com/WnghhOb3GTJ7VXXK
https://sway.office.com/tOlCaTT4fogdNrYf
https://sway.office.com/J5Fu6odSuHfoMIHG
https://sway.office.com/3iIL1t5n1rGnhxAa
https://sway.office.com/ZCmdEGirxSt2j1wn
https://sway.office.com/44JX2LKCNvtPPi0H
https://sway.office.com/ZJMsMbgMOJYWBk0B
https://sway.office.com/RXRDlystQrCMUbOz
https://sway.office.com/ntylKqlZozRQdQZ5
https://sway.office.com/jlhQsmPIQX8MmWV1
https://sway.office.com/vdrIdnveaSujIenI
https://sway.office.com/NgN6sfutPLlp3Udp
https://sway.office.com/AGaQkfvIjpdu112b
https://sway.office.com/7qdf11UvydUodCzD
https://sway.office.com/FxmjAI0ZJRtTVgCM
https://sway.office.com/QnFUvPcGEA9RXnMR
https://sway.office.com/BdHoBYTp4P25tvKl
https://sway.office.com/p0ibbZSL3Iz7baLL
https://sway.office.com/C11l1ftgbqK2UlSU
https://sway.office.com/CJdjBviw3tCUkI0L
https://sway.office.com/eQaRCDUTcZD8nrHj
https://sway.office.com/Ps86VernjEdbrDvX
https://sway.office.com/nkt69YOwM2trcDfG
https://sway.office.com/UgCBwQCLkLbU46hR
https://sway.office.com/g9dGZKMlmEJULmnZ
https://sway.office.com/bGcrkJI6OpIhzeBI
https://sway.office.com/hiwNnuWCKj02UVPV
https://sway.office.com/A7BRyt2xhOJo4dSs
https://sway.office.com/knuet5eUG1zVRdZF
https://sway.office.com/JCaQGBqAH8mAgbSa
https://sway.office.com/XoEo2xdsQA9WnrFr
https://sway.office.com/mGDJPCt1Ii5LLIdQ
https://sway.office.com/OcwEADwrtpbD91pr
https://sway.office.com/XO70oTJrtz68wWaS
https://sway.office.com/9gQxXy5xMOCnl7V2
https://sway.office.com/G1oJNpjtUbUHxUV8